Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
US-10555933-B2 · Feb 11, 2020 · US
Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
US11331306B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11331306-B2 |
| Application number | US-202016742628-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 14, 2020 |
| Priority date | Nov 21, 2011 |
| Publication date | May 17, 2022 |
| Grant date | May 17, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenylpethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating age related macular degeneration, wet macular degeneration, or dry macular degeneration in a subject in need of such treatment, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or a tautomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and wherein the pharmaceutical composition is in the form of eye drops, a slow releasing pellet, a suspension, a gel, or an intraocular implant. 2. The method of claim 1 , wherein the pharmaceutical composition is in the form of eye drops. 3. The method of claim 1 , wherein the pharmaceutical composition is in the form of a slow releasing pellet. 4. The method of claim 1 , wherein the pharmaceutical composition is in the form of a suspension. 5. The method of claim 1 , wherein the pharmaceutical composition is in the form of a gel. 6. The method of claim 1 , wherein the pharmaceutical composition is in the form of an intraocular implant. 7. A method of treating geographic atrophy in a subject in need of such treatment, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of (S) [ 3 -(1-(1H-imidazol- 4 -yl)ethyl)-2-methylphenyl] methanol, or a tautomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, and wherein the pharmaceutical composition is in the form of eye drops, a slow releasing pellet, a suspension, a gel, or an intraocular implant. 8. The method of claim 7 , wherein the pharmaceutical composition is in the form of eye drops. 9. The method of claim 7 , wherein the pharmaceutical composition is in the form of a slow releasing pellet. 10. The method of claim 7 , wherein the pharmaceutical composition is in the form of a suspension. 11. The method of claim 7 , wherein the pharmaceutical composition is in the form of a gel. 12. The method of claim 7 , wherein the pharmaceutical composition is in the form of an intraocular implant.
Assignees
Inventors
Classifications
- A61K31/4174Primary
Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole · CPC title
Ophthalmic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11331306B2 cover?
- The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenylpethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
- Who is the assignee on this patent?
- Allergan Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4174. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).